Substance Abuse Vaccines
Open accessAbstract
Conventional substance‐abuse treatments have only had limited success for drugs such as cocaine, nicotine, methamphetamine, and phencyclidine. New approaches, including vaccination to block the effects of these drugs on the brain, are in advanced stages of development. Although several potential mechanisms for the effects of antidrug vaccines have been suggested, the most straightforward and intuitive mechanism involves binding of the drug by antibodies in the bloodstream, thereby blocking entry and/or reducing the rate of entry of the drug into the central nervous system. The benefits of such antibodies on drug pharmacodynamics will be influenced by both the quantitative and the qualitative properties of the antibodies. The sum of these effects will determine the success of the clinical applications of antidrug vaccines in addiction medicine. This review will discuss these issues and present the current status of vaccine development for nicotine, cocaine, methamphetamine, phencyclidine, and morphine.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Exposure to nicotine conjugated to immunogenic proteins leads to production of IgGs, some targeted against nicotine.
“Exposure to nicotine conjugated to immunogenic proteins (e.g. cholera toxin b, a virus-like particle, and Pseudomonas exotoxin A) leads to production of IgGs, some of which will be targeted against nicotine [239, 246].”
From Mechanistic insights into nicotine withdrawal (2011) · cites this paper as [246]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Maurer, P., Jennings, G. T., Willers, J., Rohner, F., Lindman, Y., Roubicek, K., Renner, W. A., Müller, P., & Bachmann, M. F. (2005) · European Journal of Immunology · doi:10.1002/eji.200526285 · Cited by 279 · see citing works
Immunotherapy for the treatment of drug abuse
Kosten, T., & Owens, S. M. (2005) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2005.06.009 · Cited by 135 · see citing works
Hieda, Y., Keyler, D. E., Ennifar, S., Fattom, A., & Pentel, P. R. (2000) · International Journal of Immunopharmacology · doi:10.1016/s0192-0561(00)00042-4 · Cited by 97 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Mechanistic insights into nicotine withdrawal
Paolini, M., & De Biasi, M. (2011) · Biochemical Pharmacology · doi:10.1016/j.bcp.2011.07.075 · Cited by 66 · see citing works
Zheng, Z., Kyzer, J. L., Worob, A., & Wenthur, C. J. (2021) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.1c00498 · Cited by 8 · see citing works
- Authors
- Orson, F. M., Kinsey, B. M., Singh, R. A. K., Wu, Y., Gardner, T., & Kosten, T. R.
- Affiliations
- Baylor College of Medicine (US)
- Corresponding author
- Orson, Frank M.
- Venue
- Annals of the New York Academy of Sciences
- Publisher
- Wiley
- Published
- 2008-10
- Volume
- 1141
- Issue
- 1
- Pages
- 257-269
- ISSN
- 0077-8923 (ISSN-L)
- 1749-6632
- PMC
- PMC2587140
- OpenAlex
- W2088700617
- Cited by
- 79
- References
- 3
- Citations by year
- 2025: 1 · 2024: 1 · 2023: 4 · 2022: 4 · 2021: 3 · 2020: 3 · 2018: 2 · 2015: 6 · 2014: 7 · 2013: 14 · 2012: 9
- FWCI
- 1.08
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Annals of the New York Academy of Sciences (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institute on Drug Abuse (K05DA0454, K05DA000454, R01DA025223, P50DA018197, P50 DA18197)
- Topics
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Monoclonal and Polyclonal Antibodies Research
- Health Sciences › Medicine › Epidemiology › Substance Abuse Treatment and Outcomes
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Keywords
- substance abuse, addiction treatment, cocaine, nicotine, methamphetamine, phencyclidine, morphine, immunoglobulins, pharmacodynamics, vaccine development
- MeSH terms
- Animals, Immunotoxins, Antigen-Antibody Complex, Antigen-Antibody Reactions, Clinical Trials as Topic, Drug Evaluation, Preclinical, Humans, Immunoglobulin G, Illicit Drugs, Vaccines, Immunotherapy, Active, Substance-Related Disorders, Rats
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
